A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC

Inclusion Criteria:

Unresectable mRCC
Histologically or cytologically confirmed RCC of any histology
Subjects with or without prior nephrectomy
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

Any prior systemic therapy for treatment of mRCC (including investigational or licensed drugs that target VEGF or VEGF receptors/pathway, or are mammalian target of rapamycin [mTOR] inhibitors)
Central nervous system malignancies or metastases
Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders
Significant serum chemistry or urinalysis abnormalities
Significant cardiovascular disease, including symptomatic left ventricular ejection fraction or baseline LVEF of ≤ institutional lower limit of normal, uncontrolled hypertension, myocardial infarction or severe angina within 6 months prior to administration of first dose of study drug, history of class III or IV congestive heart failure, or history of serious ventricular arrhythmia, cardiac arrhythmias, or coronary or peripheral bypass graft within 6 months of screening
Corrected QT interval (QTc) of >480 msec using Bazett's formula
Currently active second primary malignancy